ストックスクリーナーアプリを入手
34.14
1.19%
-0.4015
前日終値:
$34.54
開ける：
$34.21
24時間の取引高:
874.33K
Relative Volume:
0.71
時価総額：
$7.06B
収益：
-
当期純損益:
$-505.61M
株価収益率:
-12.33
EPS:
-2.7697
ネットキャッシュフロー:
$-407.32M
1週間 パフォーマンス:
-9.35%
1か月 パフォーマンス:
-21.21%
6か月 パフォーマンス:
+43.16%
1年 パフォーマンス:
+120.76%
1日の値動き範囲:
$33.35
$34.55
1週間の範囲:
$33.35
$38.35
52週間の値動き範囲:
$15.22
$45.42
Immunovant Inc Stock (IMVT) Company Profile
Compare IMVT vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
34.16 | 7.13B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
522.86 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.74 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
186.44 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.20 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.84 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Mkt Perform |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 開始されました | Truist | Hold |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-03-03 | 開始されました | Jefferies | Hold |
| 2025-01-03 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-09 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2024-03-13 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | JP Morgan | Overweight |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
Lilly’s latest China drug deal; Immunovant’s setback in lupus - Yahoo Finance
Immunovant stock rating maintained at Buy by H.C. Wainwright - Investing.com Canada
Roivant reports top-line data from IMVT-1402 CLE trial - Yahoo Finance
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Immunovant stock falls 6.02 percent after lupus trial miss - AD HOC NEWS
Immunovant Scraps Lupus Skin Treatment After Midstage Trial Falls Short - finance.biggo.com
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program - Barron's
Why is Immunovant stock sliding today? By Investing.com - Investing.com Canada
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss - Mugglehead Investment Magazine
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Yahoo Finance
Immunovant Shares Down 6.7% Premarket After C - Moomoo
Immunovant stock falls after lupus drug trial misses goal By Investing.com - Investing.com Canada
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint - Yahoo Finance
Trial miss for Immunovant’s study of IMVT-1402 in CLE - The Pharma Letter
Immunovant halts lupus drug development after trial miss - Investing.com
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
Immunovant halts lupus drug development after trial miss By Investing.com - Investing.com Canada
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - manilatimes.net
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Immunovant stock edges lower after recent clinical pipeline focus - AD HOC NEWS
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - easternprogress.com
Immunovant stock holds gains as investors eye upcoming data and recent revenue growth - AD HOC NEWS
Kuehn Law investigates Immunovant over potential fiduciary breaches - scanx.trade
Immunovant Q1FY27 Results: $950m Moderna settlement boosts cash - scanx.trade
Immunovant Q1 2027 Earnings Call: Complete Transcript - Benzinga
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value - Yahoo Finance
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
Immunovant Inc (IMVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
Aug 28 '26 |
Sale |
43.27 |
1,500 |
64,905 |
116,731 |
| Gloria Melanie | Chief Operating Officer |
Aug 20 '26 |
Sale |
44.16 |
3,056 |
134,953 |
219,301 |
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
| Girao Tiago | Chief Financial Officer |
Jul 23 '26 |
Sale |
38.69 |
6,798 |
263,015 |
240,798 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '26 |
Sale |
38.69 |
2,857 |
110,537 |
205,341 |
| Gloria Melanie | Chief Operating Officer |
Jul 08 '26 |
Sale |
39.55 |
2,036 |
80,532 |
222,357 |
| Van Tuyl Christopher | Chief Legal Officer |
Jul 08 '26 |
Sale |
39.55 |
1,206 |
47,702 |
179,391 |
| Stout Jay S | Chief Technology Officer |
Jul 08 '26 |
Sale |
39.55 |
3,487 |
137,925 |
208,198 |
| Venker Eric | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
14.46 |
92,188 |
1,333,038 |
344,001 |
1.01%
1.44%
大文字化:
|
ボリューム (24 時間):